The rising worldwide impact of benign prostatic hyperplasia

被引:111
作者
Launer, Bryn M. [1 ]
McVary, Kevin T. [2 ]
Ricke, William A. [3 ]
Lloyd, Granville L. [4 ]
机构
[1] Univ Colorado, Anschutz Sch Med, Aurora, CO 80045 USA
[2] Loyola Univ Med Ctr, Ctr Male Hlth, Stritch Sch Med, Dept Urol, Maywood, IL 60153 USA
[3] Univ Wisconsin, George M OBrien Ctr Res Excellence, Dept Urol, Madison, WI USA
[4] Univ Colorado, Rocky Mt Reg VA Med Ctr, Dept Surg Urol, Anschutz Sch Med, 1700 N Wheeling St, Aurora, CO 80045 USA
关键词
benign prostatic hyperplasia; lower urinary tract symptoms; global health; prostate; quality of life; #UroBPH; URINARY-TRACT SYMPTOMS; QUALITY-OF-LIFE; UROLOGY; DISEASE; HEALTH; OBSTRUCTION; BLADDER; BURDEN; LUTS; MEN;
D O I
10.1111/bju.15286
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the trend in the impact of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH) on a global scale using the Global Burden of Disease (GBD) database. Materials and Methods Using the GBD database, worldwide data aggregated from registries and health systems from 1990 to 2017 were filtered for LUTS/BPH diagnoses. Calculation of years lived with disability (YLD) were compared with other urological diseases. YLD were calculated by a standardized method using assigned disability weights. The GBD-defined sociodemographic index (SDI) was used to assess impact of LUTS/BPH by global SDI quintile. Results Global Burden of Disease data over the 1990-2017 study period were summarized and global numbers and trends noted with other urological diseases for comparison. A total of 2 427 334 YLD were attributed to BPH in 2017 alone, almost three times more than those attributed to the next highest urological disease, prostate cancer (843 227 YLD). When stratified by SDI quintile, a much lower impact of BPH was found in the bottom three quintiles, despite this subset representing 66.9% of the 2017 world population. Conclusions Lower urinary tract symptoms attributed to benign prostatic hyperplasia exert a rapidly rising human burden far exceeding other urological diseases. As the population ages and men in a lower SDI enjoy increased life expectancy and decreased competing mortalities, a continually accelerating wave of LUTS/BPH can be forecast. These epidemiological trends have serious implications for the future allocation of resources and the global urological workforce.
引用
收藏
页码:722 / 728
页数:7
相关论文
共 50 条
  • [21] Depressive symptoms in patients diagnosed with benign prostatic hyperplasia
    Pietrzyk, Barbara
    Olszanecka-Glinianowicz, Magdalena
    Owczarek, Aleksander
    Gabryelewicz, Tomasz
    Almgren-Rachtan, Agnieszka
    Prajsner, Andrzej
    Chudek, Jerzy
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (03) : 431 - 440
  • [22] Referral criteria for benign prostatic hyperplasia in primary care
    Castineiras Fernandez, J.
    Cozar Olmo, J. M.
    Fernandez-Pro, A.
    Martin, J. A.
    Brenes Bermudez, F. J.
    Naval Pulido, E.
    Molero, J. M.
    Perez Morales, D.
    ACTAS UROLOGICAS ESPANOLAS, 2010, 34 (01): : 24 - 34
  • [23] Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device
    Allen, Simon
    Aghajanyan, Ivan Gerasimovich
    UROLOGY JOURNAL, 2015, 12 (05) : 2371 - 2376
  • [24] Behaviour modification and benign prostatic hyperplasia: replacement for medications
    Yap, Tet
    Emberton, Mark
    CURRENT OPINION IN UROLOGY, 2010, 20 (01) : 20 - 27
  • [25] A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia
    Kuang, Michelle
    Vu, Anthony
    Athreya, Sriharsha
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (05) : 655 - 663
  • [26] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Martinelli, E.
    UROLOGE, 2016, 55 (01): : 81 - 94
  • [27] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375
  • [28] Nocturia in men with benign prostatic hyperplasia
    Oelke, Matthias
    Fangmeyer, Bernhard
    Zinke, Joerg
    Witt, Joern H.
    AKTUELLE UROLOGIE, 2018, 49 (04) : 319 - 327
  • [29] Sexuality and Management of Benign Prostatic Hyperplasia with Alfuzosin: SAMBA Thailand
    Leungwattanakij, Somboon
    Watanachote, Damrongpun
    Noppakulsatit, Patra
    Petchpaibuol, T.
    Choeypunt, Nopporn
    Tongbai, Thanasak
    Wanamkang, Teerawan
    Lojanapiwat, Bunnakij
    Permpongkosol, Sompol
    Tantiwong, Anupan
    Pripatnanont, Chusak
    Akarasakul, Danaipan
    Kongwiwatanakul, Somsak
    Chotikawanich, Ekarat
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (09) : 3115 - 3126
  • [30] A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia
    Ullah, Rahat
    Wazir, Junaid
    Hossain, Md Amir
    Diallo, Maladho Tanta
    Khan, Farhan Ullah
    Ihsan, Awais Ullah
    Zhou, Xiaohui
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (3-4) : 153 - 162